Debra BorchardtSeptember 29, 2017
Zynerba (ZYNE) stock jumped 53% on news that its results from a Phase 2 clinical trial for lead candidate ZYN002 with Fragile-X patients had positive results. The 20-subject study showed a 46% improvement from the baseline and had meaningful improvements in key behavioral characteristics. However, Alfredo Fontanini pointed out on Twitter @AF_biotech that when you […]
